Revenue growth at Hikma to slow down after strong year

Pharmaceuticals group Hikma registered an impressive increase in revenue in 2012, helped by strong performances from both the Branded and Injectables divisions, but warned that sales growth would slow this year.

Pharmaceuticals group Hikma registered an impressive increase in revenue in 2012, helped by strong performances from both the Branded and Injectables divisions, but warned that sales growth would slow this year.

After the 20.8% growth seen in 2012, the company said that the rate would reduce to around 10% in 2013.

In 2012, group revenue increased from $918m to $1,108.7m in the 12 months to December 31st, bang in line with estimates, helped by a strong performance in its Middle East and North Africa (MENA) region, which accounts for 55.8% of group sales.

Chief Executive Officer Said Darwazah said the region is "thriving" due to the investment Hikma has made to strengthen its manufacturing and sales operations.

The generic Injectables business which accounts for 42.4% of revenue (34.4% in 2011), delivered impressive revenue growth of 48.9% last year, with the US market (63% of the division) performing strongly.

Meanwhile, the Branded division, which develops and markets branded generics and a portfolio of in-licensed products, saw revenues increase by 19.7%. This accounts for 55.8% of the whole Hikma business.

Profit before tax in 2012 jumped 40.6% from £93.9m to £132m, but growth was held back by a $20.9m operating loss in the Generics division (revenues down 33% in this unit) due to remediation work at the Eatontown facility. Compliance work was undertaken after a warning letter from US regulators in February 2012, leading to production stopping in the final two months of last year.

The full-year dividend was raised 23.1% from 13 cents per share to 16 cents per share.

"I am pleased with the very strong performance of the group this year," Said commented.

"Our focus in 2013 continues to be on building our business in MENA and on strengthening our global Injectables business. We are well positioned for 2013 and we look forward to another strong year."

Recommended

Which assets will benefit as the “jam tomorrow” bubble pops?
Investment strategy

Which assets will benefit as the “jam tomorrow” bubble pops?

With tech stocks, cryptocurrencies and many other “long duration” investments crashing hard, the “jam tomorrow” bubble looks to be bursting. John Step…
24 Jan 2022
Three innovative Asian stocks to buy now
Share tips

Three innovative Asian stocks to buy now

Professional investor Fay Ren of the Cerno Pacific Fund highlights three of her favourite Asian stocks to buy now
24 Jan 2022
Share tips of the week – 21 January
Share tips

Share tips of the week – 21 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
21 Jan 2022
Seven cheap defence stocks to buy now
Share tips

Seven cheap defence stocks to buy now

We’ve got used to a world without war between major powers, but that era is coming to an end as Russia threatens Ukraine and China eyes Taiwan. Buy de…
21 Jan 2022

Most Popular

Shareholder capitalism: why we must return power to listed companies’ ultimate owners
Investment strategy

Shareholder capitalism: why we must return power to listed companies’ ultimate owners

Under our system of shareholder capitalism it's not fund managers, it‘s the individual investors – the company's ultimate owners – who should be telli…
24 Jan 2022
Three innovative Asian stocks to buy now
Share tips

Three innovative Asian stocks to buy now

Professional investor Fay Ren of the Cerno Pacific Fund highlights three of her favourite Asian stocks to buy now
24 Jan 2022
Ask for a pay rise – everyone else is
Inflation

Ask for a pay rise – everyone else is

As inflation bites and the labour market remains tight, many of the nation's employees are asking for a pay rise. Merryn Somerset Webb explains why yo…
17 Jan 2022